The ACIP is a federal advisory committee composed of medical and public health experts who make recommendations on the use of vaccines for adults and children in the US.

Workers at the NIH sent a letter protesting the Trump administration’s cuts to the agency's budget, staff, and research.

Adding dalpiciclib to adjuvant endocrine therapy can improve outcomes in patients with HR-positive, HER2-negative early breast cancer.

Study results highlight the need to improve adverse event cost quantification in oncology cost-effectiveness analyses, researchers say.

Combining TTFields with gemcitabine and nab-paclitaxel can improve OS in patients with locally advanced pancreatic adenocarcinoma, results of the PANOVA-3 trial suggest.

HER3-DXd demonstrated activity in a phase 3 trial of patients with previously treated, EGFR-mutant NSCLC, but the BLA for HER3-DXd has been withdrawn.

Nivolumab plus ipilimumab did not improve OS vs chemotherapy in patients with previously untreated, unresectable/metastatic urothelial carcinoma.

Younger cancer survivors were more likely than their older peers to start alcohol use disorder treatment within 1 year of diagnosis. Less than 15% of cancer survivors diagnosed with alcohol use ...

Though some cancer patients lack sufficient enzymes to metabolize capecitabine or 5-FU, many patients are not warned about the risks associated with these treatments.

Pediatric patients with diffuse midline gliomas may have better outcomes if they have a more diverse gut microbiome.

The FDA has granted de novo authorization to CLAIRITY BREAST, a platform that uses AI to help predict a woman's risk of breast cancer.

Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.